Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JiPime JiPrEP Study
PACTR202004903331089Phase 4Unknown
- Sponsor
- University of Washington
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil and lamivudine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by University of Washington. Primary endpoint: Primary adherence outcome. Status: unknown.
02
Drugs
emtricitabine + tenofovir disoproxillamivudine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202004903331089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202004903331089.